International
The Morning Science

What science found today

‹
 

Research

Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer

Science · By Siqi Chen, Qishan Liu, Shubiao Ye, Jing Yu, Yongxin Xie, Yuhai Yuan, Jianning Song, Yaqing Du, Min Li, Xueli Zhang, Yanping Ma, Zhensen Lin, Yu Zhang, Xin-Yuan Guan, Guiwei He, Chen Jiang, Xiaona Fang, Xiaosheng He, Lei Li, Ping Lan & Qian Yan ·

The Brief

  • Published in Science Translational Medicine, Volume 18, Issue 876, November 2026.
  • The study reports that an anti-FOLR1 antibody-drug conjugate enhances anti-PD-1 efficacy in colorectal cancer.
  • The work is framed as targeting cancer immune evasion.

Why it matters

It suggests that combining a FOLR1-targeted antibody-drug conjugate with PD-1 blockade may improve immunotherapy response in colorectal cancer, which matters for cancer immunology research and drug development.

Who’s affected

  • cancer researchers and immunologists
  • colorectal cancer clinicians and drug developers

Science Translational Medicine, Volume 18, Issue 876 , November 2026.

Timeline

  1. Study published in Science Translational Medicine

  2. science.org

    Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer

How do you feel about this?

0 Comments

    Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti–PD-1 efficacy in colorectal cancer – The Morning Science